Мы используем Cookies Этот веб-сайт использует cookie-файлы, чтобы предлагать вам наиболее актуальную информацию. Просматривая этот веб-сайт, Вы принимаете cookie-файлы.
We also classified SqCC-derived cell lines and their reported therapeutic vulnerabilities.
2
Background: Squamous cell lung cancer (SqCC) is the second most common type of lung cancer in the United States.
3
Conclusions: Our results provide a comprehensive approach to molecular characteristics of the arsenic-exposed lung cancer genome and the non-smoking lung SqCC genome.
4
Conclusions: This study used gene expression data from a large cohort of patients to explore the molecular differences between lung ADC and SQCC.
5
Here, we review exciting work from ongoing genomic characterization and biomarker validation efforts that have nominated several likely therapeutic targets in lung SqCCs.
6
The present study focused on the clinicopathologic significance of laminin-5γ2 chain expression for local aggressiveness in lung SqCC.
7
In silico screening of candidate therapeutic compounds using subtype-specific pathway components identified HDAC and PI3K inhibitors as potential treatments tailored to lung SqCC.
8
By contrast, progress in lung SqCC has been modest, and there has yet to be a successful demonstration of targeted therapy in this disease.
9
We have assembled a rare panel of lung tumours from a population with chronic arsenic exposure, including SqCC tumours from patients with no smoking history.
10
In conclusion, both E-cadherin and vimentin are independent predictors of mortality, and the EMT phenotype is a significant indicator of poor prognosis in lung SqCC.
11
Lung squamous cell carcinoma (SqCC) is the second most common subtype of non-small-cell lung cancer and leads to 40,000-50,000 deaths per year in the USA.